Results 201 to 210 of about 203,768 (257)

Protection Against Toxoplasma gondii Lethal ME49 Challenge Induced by Influenza Virus-like Particles Containing Dense Granule Protein 14. [PDF]

Pharmaceutics
Mao J, Kang HJ, Eom GD, Heo SI, Nam H, Lee JH, Park KH, Lee MS, Kim SS, Quan FS.   +9 more
europepmc   +1 more source

Virus-like Particles Formed by the Coat Protein of the Single-Stranded RNA Phage PQ465 as a Carrier for Antigen Presentation. [PDF]

Molecules
Vasyagin EA, Mardanova ES, Ravin NV.
europepmc   +1 more source

Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy. [PDF]

Arch Razi Inst
Hadi EGG, Mostafa M, Mahdieh F, Ali Z, Majid MN.   +4 more
europepmc   +1 more source

Correction to "Dissolving Microneedle for Maintaining the Integrity of HPV Virus-Like Particles Enabling Durable Sterile Protection Across Various Mucosal Tissues". [PDF]

Adv Healthc Mater
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Transcutaneous vaccination with virus-like particles

Vaccine, 2006
Virus-like particles (VLP) are inert, empty capsids of viruses, which contain no DNA/RNA from the virus itself. However they retain the structure of a virus and they can be engineered to have antigens attached. We have constructed VLP, derived from Rabbit hemorrhagic disease virus, and shown they are highly immunogenic.
Sarah L Young, Michelle Wilson, Kenneth W Beagley   +2 more
exaly   +4 more sources

Virus-like Particles: Measures and Biological Functions

Viruses, 2022
Virus-like particles resemble infectious virus particles in size, shape, and molecular composition; however, they fail to productively infect host cells.
Tara Bhat, John Yin, Yin John
exaly   +3 more sources

Virus-like particles as immunogens

Trends in Microbiology, 2003
Subunit vaccines based on recombinant proteins can suffer from poor immunogenicity owing to incorrect folding of the target protein or poor presentation to the immune system. Virus-like particles (VLPs) represent a specific class of subunit vaccine that mimic the structure of authentic virus particles.
Rob, Noad, Polly, Roy
openaire   +2 more sources

Virus-like particles in leukaemia

Experimental pathology, 1984
Hitherto intracytoplasmic virus-like particles have not been observed simultaneously in nucleus and cytoplasm in human lymphoblasts. We analysed 20 cases of lymphoblastic leukaemia in children and found some virus-like particles in cytoplasm (12 cases) and both in nucleus and cytoplasm (4 cases).
T, Slubowski, M, Kujawa
openaire   +2 more sources

Bioengineering virus‐like particles as vaccines

Biotechnology and Bioengineering, 2013
ABSTRACTVirus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory properties of natural viruses while omitting the infectious trait. VLPs that assemble from a single protein have been shown to be safe and highly efficacious in humans, and highly profitable.
Lua, Linda H. L., Connors, Natalie K., Sainsbury, Frank, Chuan, Yap P., Wibowo, Nani, Middelberg, Anton P. J.   +5 more
openaire   +5 more sources

Recent Progress on the Versatility of Virus-Like Particles

Vaccines, 2020
Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural proteins of a virus in the absence of genetic material. Having similar morphology to natural viruses but lacking any pathogenicity or infectivity, VLPs have ...
Ciying Qian, Xinlin Liu, Tingting Li
exaly   +3 more sources